The long time between when a performance period ends and when the report comes out in the Oncology Care Model (OCM) can make it difficult to measure the impact specific changes are making, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.
The long time between when a performance period ends and when the report comes out in the Oncology Care Model (OCM) can make it difficult to measure the impact specific changes are making, said David Ortiz, OCM program director at Montefiore Einstein Center for Cancer Care.
Transcript
What differences have you seen from performance period to performance period under the Oncology Care Model?
I think the first time we started, we started late in the program, so we didn’t see any performance gains in the first performance period. But the second and third were great opportunities. I think that we’ve been able to successfully incrementally show some savings that benefit the program. I think what’s also been gained by that is that everybody is paying attention. So, now they see some benefit in the success of that effort. Now they’re all wanting and prepared to contribute. I think they didn’t know what it was all about and I think just performing and reaching those milestones—being one of the 30% in the second performance period, being one in I think it’s 30% again, being able to consistently do that from performance period to performance period that’s been a great benefit to us.
How difficult is it to make adjustments under the OCM given how much time can go by between when a performance period ends and when practices get the results of the performance period?
It’s made it a little bit of challenge, right? Because everything is retrospective and there’s no way—all throughout our attempts we’ve really tried to figure out the most proactive way of doing our forecast and how do we measure with this? It’s hard to also know that what changes we’re making now, what lasting effect it is later. So, I think that always has been the challenge with the program in terms of how it reports out.
But one thing, though, is that we’re constantly looking not just at one effort and waiting to see, we’re constantly looking at every opportunity. [Emergency department] utilization, overall usage in terms of hospice care. These are items that our feedback reports have been what keep us focused on what incremental changes we should make and can make.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More